Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 13/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | ABL2 | P42684 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2075986 | 1.00 | FBP1 (0.48) | FBP1HSP90AA1EGFRPTGS1PTGS2 | |
| SCHEMBL793300 | 0.77 | FBP1 (0.42) | FBP1HSP90AA1EGFRMAPTABL1 | |
| SCHEMBL793301 | 0.77 | FBP1 (0.42) | FBP1HSP90AA1EGFRMAPTABL1 | |
| SCHEMBL1365399 | 0.77 | FBP1 (0.48) | FBP1HSP90AA1EGFRPTGS1PTGS2 | |
| SCHEMBL8138167 | 0.77 | MAPT (0.53) | FBP1HSP90AA1MAPTRECQLALDH1A1 | |
| SCHEMBL8138170 | 0.77 | MAPT (0.53) | FBP1HSP90AA1MAPTRECQLALDH1A1 | |
| SCHEMBL1365397 | 0.77 | FBP1 (0.48) | FBP1HSP90AA1EGFRPTGS1PTGS2 | |
| SCHEMBL16785380 | 0.73 | FBP1 (0.49) | FBP1HSP90AA1EGFRMAPTALDH1A1 | |
| SCHEMBL18106502 | 0.73 | FBP1 (0.49) | FBP1HSP90AA1EGFRMAPTALDH1A1 | |
| SCHEMBL16795760 | 0.69 | PTGS1 (0.43) | PTGS1PTGS2MAPTRECQLMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101318961-B | Fused heterocyclic compound | JANSSEN PHARMACEUTICA NV | 2012-11-28 | — | — | CN | disclosed |
| US-7897771-B2 | Fused heterocyclic compounds | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-01 | — | — | US | disclosed |
| US-20110040088-A1 | FUSED HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-17 | — | — | US | disclosed |
| US-20090270370-A1 | FUSED HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-29 | — | — | US | disclosed |
| US-7579470-B2 | Fused heterocyclic compounds | JANSSEN PHARMACEUTICA NV (BE) | 2009-08-25 | — | — | US | disclosed |
| CN-101318962-A | Fused heterocyclic compound | JANSSEN PHARMACEUTICA NV (BE) | 2008-12-10 | — | — | CN | disclosed |
| CN-101318961-A | Fused heterocyclic compound | JANSSEN PHARMACEUTICA NV (BE) | 2008-12-10 | — | — | CN | disclosed |
| US-7402680-B2 | Fused heterocyclic compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-07-22 | — | — | US | disclosed |
| EP-1944306-A1 | Fused heterocyclic compounds as serotonin receptor modulators | Janssen Pharmaceutica, N.V. (BE) | 2008-07-16 | — | — | EP | disclosed |
| US-20080103132-A1 | FUSED HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2008-05-01 | — | — | US | disclosed |
| EP-1905774-A1 | Fused heterocyclic compounds as serotonin receptor modulators | Janssen Pharmaceutica, N.V. (BE) | 2008-04-02 | — | — | EP | disclosed |
| CN-1882590-A | Fused heterocyclic compounds as serotonin receptor modulators | JOHNSON & JOHNSON (BE) | 2006-12-20 | — | — | CN | disclosed |
| EP-1668014-A2 | FUSED HETEROCYCLIC COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-14 | — | — | EP | disclosed |
| US-20050119295-A1 | Fused heterocyclic compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-06-02 | — | — | US | disclosed |
| WO-2005040169-A2 | FUSED HETEROCYCLIC COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-05-06 | — | — | WO | disclosed |
| US-4148795-A | Dithiocarbamate ester bactericides and fungicides | AMERICAN CYANAMID COMPANY (US) | 1979-04-10 | — | — | US | disclosed |
| US-4038288-A | DITHIOCARBAMATE ESTER BACTERICIDES AND FUNGICIDES | AMERICAN CYANAMID COMPANY (US) | 1977-07-26 | — | — | US | disclosed |
| US-4011230-A | DITHIOCARBAMATE ESTER BACTERICIDES AND FUNGICIDES | AMERICAN CYANAMID COMPANY (US) | 1977-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119295-A1 | Fused heterocyclic compounds | TPH1, HTR3A, HTR3B | FBP1 1093/4885HSP90AA1 1676/4885EGFR 4700/4885 |
| US-20110040088-A1 | FUSED HETEROCYCLIC COMPOUNDS | TPH1, HTR3A, HTR3B | FBP1 1093/4885HSP90AA1 1676/4885EGFR 4700/4885 |
| US-20090270370-A1 | FUSED HETEROCYCLIC COMPOUNDS | TPH1, HTR3A, HTR3B | FBP1 1093/4885HSP90AA1 1676/4885EGFR 4700/4885 |
| US-20080103132-A1 | FUSED HETEROCYCLIC COMPOUNDS | TPH1, HTR3A, HTR3B | FBP1 1093/4885HSP90AA1 1676/4885EGFR 4700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.